Mission Statement, Vision, & Core Values (2025) of Granules India Limited.

An Overview of Granules India Limited

General Summary of Granules India Limited

Founded in 1984, Granules India Limited operates in the pharmaceutical sector, specializing in manufacturing Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulations, and Intermediates. The company has established a significant presence in the global market with a wide range of products targeting various therapeutic areas such as cardiovascular, anti-diabetic, and pain management.

As of 2024, Granules India has reported an impressive sales figure of approximately ₹2,200 crores (approximately USD 264 million), reflecting its robust growth trajectory in the pharmaceutical industry. The company is recognized for its cost-effective manufacturing processes and commitment to quality.

Company's Financial Performance in the Latest Financial Reports

Granules India Limited has showcased remarkable financial performance in its latest quarterly report for Q2 FY2024, detailing a record-breaking revenue of ₹650 crores for the quarter, marking an increase of 25% compared to the previous year. Notably, the sales from its primary product lines, including APIs and formulations, have contributed significantly to this growth.

The breakdown of revenue sources is as follows:

Moreover, Granules has expanded its footprint in international markets, particularly in the U.S. and Europe, contributing to a 15% increase in exports, accounting for ₹280 crores of its revenue in Q2 FY2024.

Introduction to Granules India Limited as a Leading Company in the Industry

Granules India Limited has positioned itself as a leader in the pharmaceutical manufacturing space. The company's strong focus on research and development, along with its strategic investments in technology, has enabled it to stay ahead of industry trends and maintain a competitive edge. With its commitment to sustainability and quality, Granules has earned several certifications, including ISO 9001 and WHO-GMP.

To understand more about the factors that contribute to Granules India's success in the pharmaceutical industry, you may explore detailed insights on their operational strategies, product innovations, and market expansions. This information underscores why Granules is considered a formidable player in the global pharmaceutical landscape.

Mission Statement of Granules India Limited

Mission Statement of Granules India Limited

Granules India Limited's mission statement articulates its commitment to providing high-quality pharmaceutical products and services. This mission serves as a guiding principle for the company, shaping strategic decisions and long-term objectives. The emphasis on quality, affordability, and accessibility reflects its dedication to meeting the needs of healthcare providers and patients globally.

Core Component 1: Quality

The first core component of Granules India's mission is quality. The company seeks to ensure that its products meet stringent quality standards. In fiscal year 2022-2023, Granules India reported an overall revenue of INR 1,338 crores (approximately USD 180 million), with a gross profit margin of around 40%. This indicates a commitment to maintaining high production standards while also achieving substantial financial performance.

Core Component 2: Affordability

Affordability is the second vital component of the company’s mission statement. Granules India aims to provide cost-effective solutions without compromising quality. This is evident from the company's pricing structure, where it maintains competitive pricing that adheres to market standards. For instance, the company's average selling price for key products has been 15% lower than the industry average.

Core Component 3: Accessibility

The third essential part of Granules India's mission focuses on accessibility. The company strives to make its products available to a broad spectrum of customers. Granules India has established a global distribution network that includes over 100 countries, ensuring that its products reach both emerging and developed markets. In the previous fiscal year, export revenues constituted nearly 50% of total sales, showcasing its commitment to global accessibility.

Vision Statement of Granules India Limited

Vision Statement Overview

Granules India Limited aims to enhance the quality of human life by providing high-quality pharmaceutical formulations and active pharmaceutical ingredients (APIs) at affordable prices. The company focuses on broadening its reach across the globe by ensuring innovative solutions and maintaining stringent quality standards.

Global Expansion Aspirations

Granules India Limited envisions a significant global presence by 2024. As of FY 2023, the company's international sales constituted approximately 55% of its total revenue. The target is to increase this to 70% by the end of FY 2025.

Commitment to Quality

The core aspect of Granules’ vision is its unwavering commitment to quality. The company maintains compliance with regulations from the U.S. FDA, EMA, and WHO. In FY 2023, Granules successfully passed over 12 inspections from various regulatory agencies without major observations. Furthermore, the company aims for 100% compliance rates in its manufacturing facilities by 2024.

Sustainability Goals

Granules India Limited recognizes the importance of sustainability. The company committed to reducing its carbon footprint by 30% by 2025. As part of this vision, Granules has invested approximately INR 100 crore in green initiatives and technologies over the last two years.

Innovation and R&D Focus

Innovation is critical to Granules’ long-term vision. The company has allocated about 8% of its total revenue towards research and development, amounting to approximately INR 85 crore in FY 2023. Granules aims to launch at least 5 new products yearly, targeting both domestic and international markets.

Employee Engagement

Granules India emphasizes the importance of employee engagement and development within its vision. The company aims to enhance employee satisfaction scores from 75% in FY 2023 to 90% by FY 2025. Investment in training programs increased by 20% year-over-year, reaching approximately INR 5 crore in FY 2023.

Community and Global Health Impact

Granules India is dedicated to improving global health outcomes. The company has invested over INR 15 crore in community health programs in the past year. By 2024, Granules aims to expand these initiatives, targeting a total community outreach of 1 million beneficiaries.

Core Values of Granules India Limited

Integrity

Integrity forms the foundation of Granules India Limited's operations. The company emphasizes ethical practices and accountability in all its dealings, ensuring that stakeholders trust its commitments.

In 2023, Granules India reported a revenue of ₹2,170 Crores, showcasing transparency in financial reporting. The company adheres to strict regulatory compliance, evidenced by its successful audits and certifications from global health authorities.

• Implementation of a whistleblower policy that encourages employees to report unethical practices without fear of retaliation.
• Regular training sessions for employees on ethical standards and regulatory requirements.

Innovation

Innovation drives Granules India’s growth strategy, enabling the company to adapt to changing market dynamics and customer needs.

In 2024, the firm allocated ₹150 Crores towards research and development, focusing on the development of new generic formulations and complex APIs. This investment resulted in the launch of three new products in the US market.

• Collaboration with academic institutions for cutting-edge research in pharmaceutical technology.
• Initiatives to streamline production processes, reducing operational costs by 15% in the last fiscal year.

Excellence

Granules India Limited strives for excellence in quality and operational efficiency. The company maintains rigorous quality control standards to ensure that its products meet global benchmarks.

The company achieved a 99.5% pass rate in its quality audits conducted by international regulators in 2023. Additionally, its manufacturing plants are certified by regulatory bodies such as the FDA and EMA.

• Continuous improvement programs implemented across all manufacturing sites.
• Utilization of advanced analytics for data-driven decision-making in quality management.

Collaboration

Collaboration at Granules India fosters a culture of teamwork and partnership with stakeholders, essential for long-term success.

In 2023, the company initiated over 30 strategic partnerships with global pharmaceutical firms to enhance its product portfolio and market reach.

• Joint ventures to co-develop new drug formulations aimed at addressing unmet medical needs.
• Employee engagement programs that facilitate cross-departmental collaboration, resulting in a 20% increase in project turnaround time.

Social Responsibility

Granules India is committed to making a positive impact on society through various social responsibility initiatives.

The company invested ₹50 Crores in community development projects in 2023, focusing on health care and education. Their efforts led to improved access to medical facilities for over 5,000 individuals in rural areas.

• Partnerships with NGOs to run health camps and educational programs for underprivileged communities.
• Employee volunteer programs that contribute over 10,000 hours of service annually.